NIAID, in collaboration with the Immune Tolerance Network, has completed enrollment of the adult cohort group for a clinical study of Aralast NP on preserving insulin-producing beta cell function to slow the progression of new-onset type 1 diabetes.
Read more about this study and see other studies seeking type 1 diabetes patient volunteers:
Type 1 Diabetes Studies
.png)
No hay comentarios:
Publicar un comentario